U
TRIV

UBS’s TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK TRIV Stock Holding History

UBS’s Portfolio TRIV Stock Details TRIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$4K Buy
+298
New +$4.33K ﹤0.01% 9716

Other funds holding TRIV

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS's TRIV Position: Q3 2014 in Review

UBS opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK (TRIV) in Q3 2014: 298 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #9716 among its holdings.

41 funds tracked by Wall St. Rank hold TRIV as of Q3 2014.

  • UBS held 298 shares of TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $4K as of Q3 2014.
  • TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK was a new UBS position in Q3 2014.
  • TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9716 holding.
  • 41 funds tracked by Wall St. Rank held TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.